Expanding Lithium And Iodine Production Will Meet Growing Demand In EV And Medical Markets

Published
23 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$48.52
6.1% undervalued intrinsic discount
14 Aug
US$45.54
Loading
1Y
23.2%
7D
17.8%

Author's Valuation

US$48.5

6.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 8.20%

Shared on30 Apr 25
Fair value Decreased 0.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 0.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 1.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.06%

AnalystConsensusTarget has increased revenue growth from 13.8% to 15.2%.

Shared on26 Mar 25
Fair value Increased 8.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 1.47%

Shared on10 Mar 25
Fair value Decreased 5.44%

AnalystConsensusTarget has decreased revenue growth from 13.6% to 12.1% and decreased future PE multiple from 11.4x to 10.2x.